The AHA Guidelines and Scientific Statements Handbook

The AHA Guidelines and Scientifi c Statements Handbook

14.5

0 0

2

4

6

8

10

12

14

16

Synergy death or MI at 30 days Kaplan meier curve

Percentage

UFH

Enoxaparin

0 5 10 15 20 25 30

0.8

0.85

0.9

0.95

1.0

Days from randomization

UFH

Enoxaparin

Freedom from death/MI

14

14.0

Absolute risk reduction

Hazard ratio

95% CI

P Value

0.5

0.96

0.86 to 1.06

0.40

Fig. 2.4 SYNERGY primary outcomes at 30 days.

7.3

5.7

11.7

7.7

5.3

11.8

0

2

4

6

8

10

12

14

Acuity composite

ischemia endopoint

at 30 days

Acuity major

bleeding at 30 days

Acuity net clincal

outcome at 30 days

UFH or enoxaparin + GP IIb/IIIa

Bivalirudin + GP IIb/IIIa

ARR

Risk ratio

95% CI

P

–0.4

1.07

0.92–1.23

0.007*

0.4

0.93

0.78–1.10

Less than 0.001*

–0.1

1.01

0.90–1.12

Less than 0.001*

Percentage

Fig. 2.5 ACUITY clinical outcomes at 30 days. * For noninferiority. ACUITY, Acute Catheterization and Urgent Intervention Triage strategy;
ARR, absolute risk reduction; CI, confi dence interval; GP, glycoprotein; UFH, unfractionated heparin [16].